We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Long-Term Outcomes and Prognostic Factors of High-Risk Malignant Melanoma Patients after Surgery and Adjuvant High-Dose Interferon Treatment: A Single-Center Experience.
- Authors
akman, Tulay; Oztop, Ilhan; Unek, Ilkay Tugba; Koca, Dogan; Unal, Olcun Umit; Salman, Tarık; Yavuzsen, Tugba; Yilmaz, ahmet Ugur; Somali, Isıl; Demir, Necla; Ellidokuz, Hulya
- Abstract
Background: Surgical excision constitutes an important part of the treatment of local advanced malignant melanoma. Due to the high recurrence risk, adjuvant high-dose interferon therapy is still the only therapy used in stage IIB and III high-risk melanoma patients. Methods: One hundred two high-risk malignant melanoma patients who received high-dose interferon-α-2b therapy were evaluated retrospectively. The clinicopathological features, survival times, and prognostic factors of the patients were determined. Results: The median disease-free and overall survival times were 25.2 and 60.8 months, respectively. Our findings revealed that male gender, advanced disease stage, lymph node involvement, lymphatic invasion, the presence of ulceration, and a high Clark level were significant negative prognostic factors. Conclusion: In light of the favorable survival results obtained in this study, high-dose interferon treatment as adjuvant therapy for high-risk melanoma is still an efficient treatment and its possible side effects can be prevented by taking the necessary precautions. © 2015 S. Karger AG, Basel
- Subjects
MELANOMA; THERAPEUTIC use of interferons; SURGICAL excision; CANCER relapse; RETROSPECTIVE studies; MELANOMA prognosis; ADJUVANT treatment of cancer; HEALTH outcome assessment; PATIENTS
- Publication
Chemotherapy (0009-3157), 2015, Vol 60, Issue 4, p228
- ISSN
0009-3157
- Publication type
Article
- DOI
10.1159/000371838